CLSP-1025

N/A

Report date: 2026/03/23 20:03:44

Base Information

Drug NameCLSP-1025
Drug Alias NameCLSP-1025
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionTumor protein p53 modulatorsCD3 T-cell engagers
TargetsTumor protein p53T cell surface glycoprotein CD3
Therapy Area/IndicationsSolid tumoursUrinary Bladder NeoplasmsProstatic Neoplasms +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesClasp Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesClasp Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursUrinary Bladder NeoplasmsProstatic Neoplasms +[9] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A